sl-172154
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04406623)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Delta-like protein 3INHIBITOR
DLL3 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05483933 | Phase 1 | Aug 18, 2022 | Shattuck Labs |
| NCT05275439 | Phase 1 | Mar 17, 2022 | Shattuck Labs |
| NCT04502888 | Phase 1 | Oct 31, 2020 | Shattuck Labs |
| NCT04406623 | Phase 1 | Jun 30, 2020 | Shattuck Labs |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shattuck Labs | For profit | 4 | 4 | 1 | 2020 |
1 organizations
Page 1 / 1